登录新浪财经APP 搜索【信披】查看更多考评等级 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 随着A股市场持续上行，低市值公司数量加速缩减。 8月19日，上证指数盘中一度涨至3746.67点，创下2015年8月以来近十年的高点，年初以来涨幅达 11.20%。同时，深证成指、创业板指均已突破2024年10月8日以来的高点。 伴随着大盘指数持续走强，A股低市值公司数量急剧减少。Wind数据显示，剔除已退市公司后，今年1 月初，A股市值低于20亿元的公司有594家，占A股总数比例为11.10%；截至8月19日，这一数量降至200 家，较年初减少66.33%，占比下降7个百分点。 从月度数据来看，今年前8个月中，市值低于20亿元的公司数量有6个月环比下降，其中2月末、5月末、 6月末、8月19日的环比降幅均超20%；7月末也环比下降7.35%。 数据显示，上述200家公司中，有61家公司为ST股或*ST股，占比约30%。 从申万行业来看，这200家公司中，机械设备行业数量最多，达30家；建筑装饰、基础化工、环保行业 次之，均为17家；此外，医药生物、电力设备、汽车、纺织服装等行业的公司数 ...

Summary of Key Points Core Viewpoint - The average stock price of A-shares is 12.96 yuan, with 36 stocks priced below 2 yuan, the lowest being *ST Suwu at 0.93 yuan [1] Group 1: Market Performance - As of August 19, the Shanghai Composite Index closed at 3727.29 points, with a notable presence of low-priced stocks in the market [1] - Among the low-priced stocks, 22 out of 36 saw an increase in price, with Shandong Steel, Pubang Co., and Rongsheng Development leading the gains at 2.63%, 2.17%, and 2.10% respectively [1] - Conversely, 7 stocks experienced declines, with *ST Suwu, *ST Gaohong, and *ST Yunwang showing the largest drops at 5.10%, 4.91%, and 1.57% respectively [1] Group 2: Low-Priced Stocks Overview - The list of stocks priced below 2 yuan includes 13 ST stocks, accounting for 36.11% of the low-priced segment [1] - The lowest priced stock is *ST Suwu at 0.93 yuan, followed by *ST Jinke at 1.39 yuan and Yongtai Energy at 1.44 yuan [1] - The trading characteristics of these low-priced stocks show varying turnover rates, with *ST Suwu having a turnover rate of 7.60% [1] Group 3: Detailed Stock Data - A detailed table lists various low-priced stocks, their latest closing prices, daily price changes, turnover rates, and industry classifications [1][2] - For instance, *ST Suwu is in the pharmaceutical sector, while *ST Jinke and Yongtai Energy belong to real estate and coal industries respectively [1] - Other notable stocks include Shandong Steel and Rongsheng Development, both in the steel and real estate sectors, showing positive daily changes [1]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Views - The report highlights the release of the preliminary list of innovative drugs for commercial insurance, focusing on companies with leading clinical value and commercialization capabilities [4] - The pharmaceutical and biotechnology industry index increased by 2.21%, ranking 21st among 31 primary industries, underperforming the CSI 300 index which rose by 3.64% [5][16] - The report suggests a focus on companies in the oncology, metabolic diseases, and rare diseases treatment sectors, particularly those with strong clinical pipelines and commercialization capabilities [8] Industry Overview - The pharmaceutical and biotechnology industry PE (TTM, excluding negative values) as of August 15, 2025, is 31.38x, up from 30.97x in the previous period, indicating an upward valuation trend but still below the average [5][21] - The top three sub-industries by PE are vaccines (62.98x), hospitals (40.19x), and medical consumables (39.11x), while the lowest is pharmaceutical distribution (15.85x) [21] Important Industry News - The National Healthcare Security Administration (NHSA) has published the preliminary list of innovative drugs for commercial insurance, with over 100 innovative drugs included, covering areas such as oncology and rare diseases [8][26] - The NHSA is also advancing the reform of medical insurance payment methods, emphasizing a disease-based payment model to enhance the quality of healthcare services [30] Company Dynamics - Insmed's "Brensocatib" has received FDA approval for treating non-cystic fibrosis bronchiectasis, marking a significant advancement in targeted therapies for this condition [42][44] - Precigen's "Papzimeos" has been approved by the FDA as the first-in-class gene therapy for recurrent respiratory papillomatosis, providing a new treatment option for patients [48] - The approval of "博优平" (Dulaglutide injection) by 博安生物 marks it as the first domestically produced biosimilar of its kind, aiming to compete in the diabetes treatment market [49][50]

2025 年 8 月 15 日，公司通过中国证券登记结算有限责任公司系统查询获悉， 公司控股股东苏州吴中投资控股有限公司股份被轮候冻结，具体情况如下： 二、股东股份累计被冻结情况 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-086 江苏吴中医药发展股份有限公司 关于公司控股股东所持股份被轮候冻结的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 三、其他情况说明 3、公司将进一步向控股股东核实上述事项相关情况，并将持续关注控股股 东持有的公司股票被司法冻结、标记以及债务风险化解情况，及时履行信息披露 义务。敬请广大投资者理性投资，注意投资风险。 截至本公告披露日，控股股东所持公司股份累计被冻结（包括司法冻结、司 股东名称 是否为 控股股 东 冻结股份数量 （股） 占其所持 股份比例 占公司总 股本比例 冻结股份 是否为限 售股 冻结起始日 冻结到期日 冻结申请 人 冻结原 因 苏州吴中 投资控股 有限公司 是 122,795,762 100.00% 17.27% 否 2025-08-1 ...

Summary of Key Points Core Viewpoint - The average stock price of A-shares is 12.79 yuan, with 39 stocks priced below 2 yuan, the lowest being *ST Suwu at 0.94 yuan [1] Group 1: Market Performance - As of August 15, the Shanghai Composite Index closed at 3696.77 points, with a total of 39 stocks trading below 2 yuan [1] - Among the low-priced stocks, 30 experienced price increases, with *ST Yunwang, ST Zhongzhu, and *ST Yangguang showing gains of 5.03%, 4.44%, and 3.37% respectively [1] - Conversely, 3 stocks declined, with *ST Suwu, *ST Gaohong, and Meike Home showing decreases of 5.05%, 4.97%, and 1.00% respectively [1] Group 2: Low-Priced Stocks Overview - The list of low-priced stocks includes *ST Suwu (0.94 yuan), *ST Jinke (1.41 yuan), and Rongsheng Development (1.42 yuan) [1] - A total of 13 out of the 39 stocks priced below 2 yuan are ST stocks, accounting for 33.33% of this group [1] - The highest daily turnover rates among low-priced stocks were observed in *ST Yunwang (3.96%) and ST Zhongzhu (3.99%) [2]

证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-085 江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、公司关注并核实的相关情况 （一）生产经营情况 经自查，除公司已披露的事项外，截至本公告披露日，公司日常生产经营及 外部环境未发生其他重大变化。 重要风险提示： 江苏吴中医药发展股份有限公司（以下简称"公司"）股票连续三个交 易日内收盘价格跌幅偏离值累计超过 12%，属于股票交易异常波动的情形。 2025 年 7 月 13 日，公司收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《行政处罚事先告知书》（处罚字〔2025〕58 号），具体 内容详见公司于 2025 年 7 月 14 日披露的《关于收到中国证券监督管理委员会< 行政处罚事先告知书>的公告》（公告编号：临 2025-064）。公司股票已于 2025 年 7 月 14 日起被叠加实施退市风险警示，如根据中国证监会正式的处罚决定书 结论，公司触及重大违法强制退市情形，公司股票将被终 ...

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 黔南州医疗监测上半年医疗追溯救助1600余人 贵州日报8月14日消息显示，今年上半年，黔南州城乡居民参保347.13万人，其中119.07万特殊困难群众 实现参保全覆盖。 今年1月至6月，黔南州特殊困难群众住院发生医疗总费用2.82亿元，三重医疗保障报销达2.44亿元。黔 南州医疗监测预警的7233人次均反馈到农业农村部门纳入监测范围，经认定符合政策的及时纳入民政救 助和医疗救助范围，其中医疗追溯救助1671人，共计679.35万元。 天津医保拟发新规：黄牌警示，红牌"罚下" 8月12日，天津市医保局网站发布"关于征求《天津市定点医药机构实施预警亮牌管理机制(试行)（征求 意见稿）》意见的通知"。天津拟对定点医药机构实施预警亮牌管理机制。 医保经办机构每季度对被警示机构出示黄牌。对被黄牌警示机构，医保经办机构加大管理力度，暂停拨 付费用一至三个月。 对于一个自然年度内累计受到两次黄牌警示的机构，医保经办机构出示红牌，中止医保协议一至三个 月，中止期间发生的医保费用不予结算，并向社会公示。 被警示机构应按照相 ...

Core Viewpoint - A legal dispute has arisen over the exclusive distribution rights of the AestheFill product, with *ST Suwu's subsidiary, Datou Medical, seeking arbitration against Aimeike's subsidiary, Regen, for breach of contract and claiming damages of up to 1.6 billion yuan [2][3]. Group 1: Legal Dispute - Datou Medical has filed for arbitration with the Shenzhen International Arbitration Court, accusing Regen of breaching the exclusive distribution agreement for AestheFill [2][3]. - Regen's reasons for termination include alleged unauthorized transfer of distribution rights and violations of securities laws by *ST Suwu's executives, which they claim have harmed the product's reputation [3][4]. - *ST Suwu refutes these claims, asserting that no transfer of rights occurred and that the agreement does not allow for termination based on administrative penalties against its executives [3][4]. Group 2: Financial Performance - AestheFill has generated over 3 billion yuan in sales within just eight months, achieving an 82% gross margin, significantly contributing to *ST Suwu's turnaround from losses [2][6]. - In 2024, AestheFill's sales revenue reached 326 million yuan, accounting for 20.42% of *ST Suwu's total revenue, with a gross profit of 269 million yuan, representing 34.80% of the company's gross profit [6]. - The medical aesthetics segment of *ST Suwu reported a revenue increase of 4225.65% year-on-year, with a gross margin of 82.26% in 2024 [6]. Group 3: Market Context - AestheFill, known as the "童颜针" (youthful needle), is a high-margin product that has quickly gained market share in the aesthetic medicine sector, despite its higher price compared to similar products from Aimeike [6][7]. - Aimeike's revenue growth has slowed significantly, with a projected 2024 revenue of 3.026 billion yuan, reflecting a growth rate of only 5.45%, down from over 47% in 2023 [5]. - The overall medical aesthetics market in China is expected to grow at a rate of 10% to 15% in the coming years, indicating a competitive landscape for companies like Aimeike and *ST Suwu [5].

Core Viewpoint - The commercial dispute over the exclusive distribution rights of the "AestheFill" product between Jiangsu Wuzhong and Regen Biotech has escalated, leading to significant implications for both companies and the medical aesthetics industry as a whole [2][3][4]. Group 1: Company Actions and Responses - Jiangsu Wuzhong announced that it would seek arbitration to confirm the validity of the exclusive distribution agreement and is claiming damages of 1.6 billion yuan, covering development costs and potential profits [8]. - Following the receipt of a termination letter from Regen, Jiangsu Wuzhong initiated a legal response, asserting that there was no transfer of exclusive rights and that the termination was unjustified [6][11]. - Aimeike, which has taken operational control of Regen, has been accused by Jiangsu Wuzhong of manipulating the situation to undermine its distribution rights [17]. Group 2: Financial Impact - Jiangsu Wuzhong's stock price has dropped over 40% since receiving the termination notice, with its market capitalization falling to 704 million yuan [3]. - The "AestheFill" product has been a significant revenue driver for Jiangsu Wuzhong, contributing 3.26 billion yuan in sales in its first year and 1.13 billion yuan in the first quarter of 2025 [9]. - The company reported a net profit of 70.48 million yuan in 2024, a 197.97% increase, largely attributed to the success of "AestheFill" [9]. Group 3: Industry Implications - The dispute has created uncertainty in the medical aesthetics industry, potentially causing anxiety among distributors and affecting market dynamics [3][12]. - The conflict highlights deeper issues within the industry regarding the balance of power between brand owners and distributors, with the latter often feeling insecure in their roles [17]. - Aimeike is also facing its own growth challenges, with a significant slowdown in revenue growth, indicating that the competitive landscape is becoming increasingly difficult for all players involved [13].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is facing potential delisting due to significant violations of information disclosure regulations, as identified by the China Securities Regulatory Commission (CSRC) [2][4][10] Group 1: Investigation and Penalties - The company has been under investigation by the CSRC since February 26, 2025, for suspected violations of information disclosure laws [3] - On July 13, 2025, the CSRC issued a notice indicating that the company inflated revenue, costs, and profits from 2020 to 2023, leading to significant discrepancies in financial reporting [4] - The inflated figures included revenue increases of CNY 495.26 million, CNY 468.51 million, CNY 430.75 million, and CNY 376.66 million for the respective years, representing 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues [4] Group 2: Potential Delisting Risks - If the formal penalty decision confirms the violations, the company may face mandatory delisting under the Shanghai Stock Exchange rules [2][5] - The company will apply for a trading suspension and disclose relevant information if it receives a formal penalty decision indicating delisting risks [7] - The stock price closed at CNY 0.99 on August 14, 2025, falling below the CNY 1 threshold, which could also lead to delisting if it remains below this price for 20 consecutive trading days [10][11] Group 3: Compliance and Future Actions - The company is committed to cooperating with the CSRC and will exercise its rights to defend against the allegations [2][5] - The company will continue to fulfill its information disclosure obligations as required by regulations [5][6]